Our Team
dedicated to science, medicine, and business
Michael P. Bevilacqua, M.D., Ph.D.
CEO, CSO, Director & Co-Founder
Dr. Bevilacqua has 30+ years’ experience as a medical scientist, inventor, and business executive. He served on the faculty of the Department of Pathology at Brigham and Women's Hospital and Harvard Medical School, where he led a successful research laboratory and was named a PEW Scholar. He was then chosen as a Howard Hughes investigator and joined the faculty at UCSD Medical Center. In 1993, he took his first corporate position as Vice President of Amgen and built a division for inflammatory and immunological diseases. Subsequently, Dr. Bevilacqua has worked with start-up corporations in both therapeutics and diagnostics. His scientific work has led to numerous patents and publications.
Timothy J. Deming, Ph.D.
Head of SAB & Co-Founder
Professor Deming’s pioneering work on controlled synthesis and characterization of amino acid polymers provided foundational technology for Macro Biologics. He has published more than 120 articles and 16 patents. Professor Deming’s research uses innovative chemistry to synthesize and characterize complex biomaterials based on amino acids. He has led successful research programs at UCSB and served as Chair of the UCLA Bioengineering Department.
Daniel J. Gowen-Huang, MBA
Chief Operating Officer
Mr. Gowen-Huang oversees corporate internal operations, including financial accounting, project and data management, and facilities. In addition, he oversees key outside interactions with government/NGO funding organizations, as well as those with contract research/manufacturing organizations. His interdisciplinary expertise in R&D and financial management help drive Macro Biolologics’ innovative product development efforts.
Eric Roche, Ph.D.
Vice President of Preclinical Development
​
Dr. Roche leads Macro's non-clinical pharmacology and GLP toxicology efforts. He has 17+ years’ experience in biopharmaceutical R&D, including 8 years as R&D Manager with Smith & Nephew, as well as principal/senior research scientist positions over an additional 9 years. Dr. Roche completed his post-doc at Harvard Medical School, received his PhD in Biology from MIT, and received his BA magna cum laude in Chemistry at Rice University.
Shalyn DeWall
Director of Biomaterials​
​
Mrs. DeWall is an R&D scientist with experience in product development of FDA-regulated products. At Macro Biologics, Mrs. DeWall plays an important role in management of our product programs, with an emphasis on logistics and on drug substance and drug product manufacturing.
Eric Rusaw
Director of Corporate Development
Mr. Rusaw is helping drive Macro’s efforts in multiple efforts, especially in corporate communications and finance. He has a broad background in business management ranging from marketing to finance and banking to operations.
Board of Directors
Michael Flesch
Chairman & Co-Founder
Mr. Flesch is Chairman & CEO of Safety Investment Company, a private investment company focused on real estate, a venture capitalist, and former litigation attorney at Brobeck Phleger & Harrison, representing primarily Fortune 500 companies.​ He has been a member of the Board of Directors of the UCLA Foundation and a Trustee of Occidental College, serving on finance and investment committees at both universities. Mr. Flesch is also Founder and Chairman of Bruin Biometrics, a medical device company developing systems that cost-effectively detect and monitor select medical conditions.
Mark Thompson
Director
Mr. Thompson co-founded Riverbridge Partners in 1987. As chief manager, he is responsible for the strategic decision-making and overall management of the firm. He is also chairman of the Riverbridge Board of Governors. Mr. Thompson is a member of the CFA Institute and the CFA Society of Minnesota. Mark is also a member of the Board of Directors of Endurance Capital, Wiland Direct, Inc., TreeHouse, Opportunity International Nicaragua, Motivation AI, Inc., as well as a trustee of the LoCorr mutual funds and the Board of Investment – Converge Retirement Fund. Mr. Thompson earned his Bachelor of Science in Business in Finance from the University of Minnesota Carlson School of Management.
Glen March, M.D.
Director
Dr. March is an Ophthalmologist with training in Neuro-Ophthalmology at Harvard Medical School/Massachusetts Eye & Ear Infirmary, and Orbital and Ophthalmic Plastic Surgery at UCLA/Jules Stein Eye Institute. He co-founded March Vision Care, the first minority owned vision plan in 2001. The company grew to over 7 million members in 26 states and the District of Columbia. He functioned as Chairman and CEO until its sale to United Healthcare (NYSE:UNH) in 2016. He is co-principal at Strategem Investments, LLC, a private equity firm focused on early-stage funding of innovative ideas. Local community board positions include: the Ahmanson Foundation and the Metropolitan LA YMCA.
Martin Burns, MBA
Director
Mr. Burns is CEO of Bruin Biometrics, an innovative medical device company developing systems that cost-effectively detects and monitors select medical conditions. Appointed CEO in 2012, he established and led the successful journey of BBI’s SEM Scanner through FDA de novo Marketing Authorization (2018), CE Marking (2013) and the UK's National Institute of Health and Care Excellence (NICE) Medical Innovation Briefing process (MIB 182, 2019). Previously, he spent more than 15 years as a management consultant at Deloitte and PricewaterhouseCoopers. Mr. Burns has led corporate strategy, innovation, operations, quality and regulatory, M&A and global expansion assignments for medical device and life sciences companies. He earned his BA (1996) at the London School of Economics and Political Science (LSE) and his MBA at UCLA’s Anderson School of Management (2007).
Michael P. Bevilacqua, M.D., Ph.D.
CEO, CSO, Director & Co-Founder
See above.